Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy

Yuichi Yamazaki, Satoru Kakizaki, Yuki Tamura, Yumeo Tateyama, Tatsuma Murakami, Takuya Adachi, Hiroki Tojima, Toshio Uraoka · 2026

Read Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy by Yuichi Yamazaki, Satoru Kakizaki, Yuki Tamura, Yumeo Tateyama, Tatsuma Murakami, Takuya Adachi, Hiroki Tojima, Toshio Uraoka (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13600002.txt.

Description

Two immune drugs given together fight several cancers well, but the pair can badly inflame the liver. Yuichi Yamazaki and co-authors hunt for warning signs in this 2026 study of 81 patients treated between 2018 and 2025. Severe liver injury struck 11 patients, about 14 percent, at a median of 38 days after the first dose.

A blood marker called KL-6, at or above 400 units before treatment, flagged risk strongly, with odds about thirteen times higher. Standard liver tests gave no such warning. Over half the severe cases resisted steroids or flared as doses tapered. A hidden virus, cytomegalovirus, had reawakened in half of those tested. The authors suggest checking KL-6 first and screening for the virus when steroids fail.

Catalog record

CREATORYuichi Yamazaki, Satoru Kakizaki, Yuki Tamura, Yumeo Tateyama, Tatsuma Murakami, Takuya Adachi, Hiroki Tojima, Toshio Uraoka
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13600002

Browse the full library · About the Tower of Babel